Back to first-pass browser

First-pass extracted concept

engineered NK cells

Candidate: concept label1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

engineered natural killer cells, genetically modified NK cells

Extracted Explainers

What the tool is doing

Engineered NK cells are presented as genetically modified natural killer cells developed for cancer immunotherapy. The review frames them as a way to improve NK-cell therapeutic performance.

Source 1DOIPubMed

Resources required

The abstract indicates that genetic modification of NK cells is required, including viral and non-viral approaches. No specific construct or manufacturing protocol is given in the abstract.

Source 1DOIPubMed

What problem it solves

They are described as addressing poor expansion, inactivation, insufficient tumor infiltration, and limited in vivo persistence of unmodified NK cells in the tumor microenvironment.

Source 1DOIPubMed

What it does not solve

The abstract does not claim that engineered NK cells fully overcome all tumor microenvironment barriers or provide complete clinical efficacy across settings.

Source 1DOIPubMed

Alternatives

The abstract contrasts NK-cell therapy with CAR-T cell therapy and also refers to unmodified NK cells as a less engineered alternative.

Source 1DOIPubMed

Evidence Snippets

Advances in the genetic modification of NK cells can address some of these limitations and improve their therapeutic efficacy. In this review, we describe the advances in the development of engineered NK cells for cancer immunotherapy.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1comparative safetysupports2025Source 1DOIPubMed

NK cell-based therapies are described as safer than T-cell-based therapies because NK cells do not express TCR and are not associated with cytokine release syndrome or graft-versus-host disease.

Quoted textsource-backed
As they do not express T cell receptor (TCR), NK cell-based therapies are not associated with cytokine release syndrome (CRS) or graft versus host disease (GvHD), which enables a safer therapy and the ability to generate an allogeneic "off-the-shelf" product.
Claim 2engineering rationalesupports2025Source 1DOIPubMed

Genetic modification of NK cells can address limitations of unmodified NK cells and improve therapeutic efficacy.

Quoted textsource-backed
Advances in the genetic modification of NK cells can address some of these limitations and improve their therapeutic efficacy.
Claim 3therapeutic limitationsupports2025Source 1DOIPubMed

Unmodified NK cells have compromised therapeutic application because the inhibitory tumor microenvironment causes poor expansion, inactivation, insufficient tumor infiltration, and limited in vivo persistence.

Quoted textsource-backed
Despite the innate cytotoxic activity of NK cells against malignant cells, the therapeutic application of unmodified NK cells has been compromised by the inhibitory tumor microenvironment (TME), which is responsible for poor cell expansion, inactivation, insufficient tumor infiltration, and limited in vivo persistence, leading to the dysfunction of NK cells after infusion.